Condition

Systemic Lupus Erthematosus (SLE)

ClinicalTrials.gov condition label

Clinical trials9

Recruiting5

Common interventions11

Lead sponsors shown7

Clinical trials

9 shown

2-HOBA in Systemic Lupus ErythematosusNCT07225543 · 2026-05-15

CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseNCT07586267 · 2026-05-08

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseNCT07507201 · 2026-04-01

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseNCT07305116 · 2025-12-01

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyNCT07150000 · 2025-04-01

Team-based Implementation of Hypertension Management in Childhood LupusNCT07792733 · 2027-04-01

NOT_YET_RECRUITING

A Basket Study of CTA313 in Participants With Active Autoimmune DiseasesNCT07783269 · 2026-12-01

NOT_YET_RECRUITING

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune DiseaseNCT07729995 · 2026-10-01

NOT_YET_RECRUITING

A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNCT07593911 · 2026-06-01

NOT_YET_RECRUITING

Common interventions

UCAR T-cellBIOLOGICAL2 2-HOBA acetate (2-Hydroxybenzlamine acetate)DRUG1 CTA313 UCAR T Cell InfusionDRUG1 Ex Vivo AssayDIAGNOSTIC_TEST1 Health Navigator EngagementOTHER1 LMY-922BIOLOGICAL1 MTM-H-001 InjectionDRUG1 PlaceboDRUG1 Pre-visit worksheetOTHER1 QT-219CXBIOLOGICAL1 Team Charter with Performance MonitoringOTHER1

Leading sponsors

The Children's Hospital of Zhejiang University School of Medicine3 Beijing GoBroad Hospital1 Boston Children's Hospital1 Imviva Bio1 Luminary Therapeutics1 University of Bonn1 Vanderbilt University Medical Center1

Trial status mix

RECRUITING5

NOT_YET_RECRUITING4

Phase mix

PHASE13

EARLY_PHASE12

NA2

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.